Advanced Unresectable Melanoma clinical trials

Explore recruiting advanced unresectable melanoma clinical trials.

Recruiting advanced unresectable melanoma studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Advanced Unresectable Melanoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Efficacy and Safety Study of Acasunlimab as Monotherapy and in Combination With Pembrolizumab in Subjects With Relapsed/Refractory, Unresectable Locally Advanced or Metastatic Cutaneous Melanoma That Progressed On or After Treatment With a Checkpoint Inhibitor

France, Spain, Netherlands, Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Advanced Unresectable Melanoma trials by city

Advanced Unresectable Melanoma clinical trials

Recruiting advanced unresectable melanoma studies right now

AMT-253 in Patients With Advanced Solid Tumours

A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel

Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma

A Beta-only IL-2 ImmunoTherapY Study

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

Mirdametinib in Patients With Advanced NF1-mutant Melanoma

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Neoadjuvant Tebentafusp for Uveal Melanoma

Also recruiting in Europe

Efficacy and Safety Study of Acasunlimab as Monotherapy and in Combination With Pembrolizumab in Subjects With Relapsed/Refractory, Unresectable Locally Advanced or Metastatic Cutaneous Melanoma That Progressed On or After Treatment With a Checkpoint Inhibitor

Advanced Unresectable Melanoma trials by city

Other conditions